Aarti Pharmalabs

Aarti Pharmalabs The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates and Xanthine Derivatives in India. Aarti Pharmalabs Limited was initially incorporated as 'Aarti Organics Limited' in 2019. The name of the Company was changed to Aarti Pharmachem Limited from Aarti Organics Limited' in July, 2021 and to Aarti Pharmalabs Limited in 2022. Company is a manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine derivatives situated in India. It specialise in developing and manufacturing Highly Potent Active Pharmaceutical Ingredients (HPAPIs) critical for various therapeutic segments such as Anti-cancer, Anti-Asthma, Anti-Hypertensive etc. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022. In 2021-22, the Pharmaceutical Division was demerged from Aarti Industries Limited into its wholly owned subsidiary, Aarti Pharmalabs Limited, via Scheme of Arrangement for Demerger, thus making it effective on October 17, 2022 and operational from July 1, 2021. Thereafter, Company commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023. The R&D centre in Nerul, Navi Mumbai became fully operational in FY 2024. The Company commenced operations for its semi-commercial block at the USFDA intermediate manufacturing site in Vapi in FY24. The Xanthine capacity enhanced to 5000 TPA in 2024.